These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11957763)

  • 1. Tamsulosin: effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real-life practice in Spain.
    Batista JE; Palacio A; Torrubia R; Hernández C; Vicente J; Resel L;
    Arch Esp Urol; 2002; 55(1):97-105. PubMed ID: 11957763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.
    Palacio A; Hernández C; Marqués A; Prats J; Espinosa FJ
    Arch Esp Urol; 2004 May; 57(4):451-60. PubMed ID: 15270291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
    Barqawi AB; Myers JB; O'Donnell C; Crawford ED
    BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
    Gross AJ; Busse M; Leonard J; Schumacher H
    Prostate Cancer Prostatic Dis; 2005; 8(3):210-4. PubMed ID: 15883586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of patient-reported outcome of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and treated with tamsulosin HCl in Korea.
    Chang HS; Park CH; Kim DK; Park JK; Hong SJ; Chung BH; Lee JG; Kim CS; Lee KS; Kim JC
    Urology; 2010 May; 75(5):1156-61. PubMed ID: 19914692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia.
    Ichioka K; Ohara H; Terada N; Matsui Y; Yoshimura K; Terai A; Arai Y
    Int J Urol; 2004 Oct; 11(10):870-5. PubMed ID: 15479292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS).
    Hoesl CE; Woll EM; Burkart M; Altwein JE
    Eur Urol; 2005 Apr; 47(4):511-7. PubMed ID: 15774251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
    Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
    BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
    Elhilali M; Emberton M; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Alcaraz A; Vallancien G;
    BJU Int; 2006 Mar; 97(3):513-9. PubMed ID: 16469018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.